K-biotech scores back-to-back mega deals worth nearly $2 billion in a single day

South Korea's biotech industry rattled global markets Monday as two domestic companies announced back-to-back technology licensing deals totaling 2.9 trillion won in a single day.

Industry observers say the deals mark a decisive qualitative leap for K-biotech — moving beyond the era of headline-grabbing but hollow trillion-won contracts toward agreements that secure substantial upfront cash from global partners, reflecting genuine advances in domestic drug development capabilities.

Hanmi Pharmaceutical and Oscotec each signed major license-out agreements Monday — Hanmi with global pharmaceutical giant Eli Lilly and Oscotec with U.S. rare-disease specialist Agios Pharmaceuticals — valued at approximately 1.9 trillion won ($1.26 billion) and 1 trillion won, respectively.

That two domestic companies — a biotech venture and a traditional pharmaceutical firm — closed combined deals worth roughly 2.9 trillion won within two days is extraordinarily rare in the history of Korean drug development.

Hanmi Pharmaceutical's achievement is particularly significant as a comeback for one of Korea's most established pharmaceutical players. The company signed a technology licensing deal with Lilly in 2015 for a BTK inhibitor targeting immune diseases, only to have the rights returned in 2019. Monday's agreement marks Hanmi's first major technology export with Lilly in 11 years.

The compound Hanmi licensed out, sonepeglutide, is a candidate treatment for short bowel syndrome, a rare disease, developed using the company's proprietary drug-duration platform known as LAPSCOVERY.

The deal carries particular weight given that Lilly — the dominant force in the global obesity and metabolic disease market — committed $75 million (approximately 112.9 billion won) in non-refundable upfront payments, a clear endorsement of Hanmi's platform technology. Having a rare-disease asset at the Phase 2 trial stage valued at $1.26 billion (approximately 1.9 trillion won) total is considered an exceptionally strong deal even by global drug licensing standards.

Hanmi Group Vice Chairman Lim Joo-hyun said the deal was deeply meaningful because Lilly, one of the world's most closely watched innovators, had recognized sonepeglutide's development potential. "Hanmi Pharmaceutical will continue to pursue our mission of respect for humanity and value creation through the development of innovative new drugs," Lim said.

Oscotec's own trillion-won windfall on the same day is equally remarkable. The company previously transferred the original compound behind lung cancer drug Lazertinib (brand name: Leclaza) to Yuhan Corporation, helping lay the groundwork for its global commercialization. Monday's deal is its third technology export since its founding.

The asset Oscotec licensed to Agios is sevidoplenib, an oral candidate treatment for autoimmune diseases. The compound has completed global Phase 2 trials for immune thrombocytopenia and rheumatoid arthritis, accumulating safety and efficacy data, and has received orphan drug designation from the U.S. Food and Drug Administration.

Oscotec secured $25 million (approximately 37.5 billion won) in non-refundable upfront payments, which it will split with its subsidiary Genosco in a 75-to-25 ratio. The deal gives Oscotec the financial resources to redirect its core mid- to long-term research and development efforts toward next-generation drug-resistance anticancer treatments.

Oscotec CEO Yoon Tae-young said he expected sevidoplenib to build on Agios's expertise in rare immune diseases and pursue multiple indications, ultimately becoming a globally approved drug that brings hope to patients worldwide.

Industry insiders say the consecutive mega-deals serve as a definitive indicator of K-biotech's structural maturation. In the past, Korean companies' technology exports were often criticized for inflated headline figures — assets handed over cheaply at the preclinical stage, with low upfront payment ratios that left companies exposed to the risk of rights being returned if clinical trials failed.

The Hanmi and Oscotec deals, by contrast, were built on high-quality data accumulated through global Phase 2 trials. The ratio of upfront payments to total contract value has risen sharply, and both partners are leading global pharmaceutical companies with world-class clinical development and commercialization capabilities in their respective rare and metabolic disease fields — a structure designed to maximize both contractual security and the probability of commercial success.

"Hanmi's reunion with Lilly after 11 years and Oscotec's third technology export are proof that Korean drug R&D is fully recognized in the global market," one industry official said. "As both companies use the upfront cash inflows to reinvest in follow-on pipeline R&D, they are establishing a virtuous cycle that will accelerate K-biotech's global influence even further."